Atea Pharmaceuticals, Inc. (AVIR) Financials

AVIR Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 267.1 million 33.4 million
Dec. 31, 2025 315.2 million 39.8 million
Sept. 30, 2025 343.0 million 27.2 million
June 30, 2025 391.6 million 27.2 million

AVIR Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -46.4 million 3.7 million
Dec. 31, 2025 -28.2 million 4.6 million
Sept. 30, 2025 -40.4 million 4.5 million
June 30, 2025 -32.9 million 4.7 million

AVIR Net Income

No data available :(

AVIR Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 256.0 million - -
Dec. 31, 2025 301.8 million - 843000
Sept. 30, 2025 329.3 million - 1.0 million
June 30, 2025 379.7 million - 1.2 million

AVIR Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 79.2 million
Dec. 31, 2025 78.1 million
Sept. 30, 2025 79.1 million
June 30, 2025 83.7 million

AVIR Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 41.1 million 6.9 million -
Dec. 31, 2025 - 47.8 million 7.1 million -
Sept. 30, 2025 - 38.3 million 7.2 million -
June 30, 2025 - 32.3 million 9.1 million -

AVIR Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 104000
Dec. 31, 2025 - 104000
Sept. 30, 2025 - -
June 30, 2025 - 2.4 million

AVIR

Price: $4.73

52 week price:
2.78
6.45

Earnings Per Share: -2.11 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 884000

Ebitda: -17.0 million

Market Capitalization: 395.3 million

Links: